| 前收盘价格 | 79.50 |
| 成交量 | 1,977,446 |
| 价格/销量 (P/S) | 23.23 |
| 股市价格/股市净资产 (P/B) | 5.00 |
| 52周波幅 |
| 营业毛利率 | -120.35% |
| 营业利益率 (TTM) | -62.30% |
| 稀释每股收益 (EPS TTM) | -2.16 |
| 季度收入增长率 (YOY) | 1,284.60% |
| 总债务/股东权益 (D/E MRQ) | 30.43% |
| 流动比率 (MRQ) | 3.30 |
| 营业现金流 (OCF TTM) | -789.63 M |
| 杠杆自由现金流 (LFCF TTM) | -565.77 M |
| 资产报酬率 (ROA TTM) | -10.23% |
| 股东权益报酬率 (ROE TTM) | -18.85% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | KEYMED BIO-B | - | - |
AIStockmoo 评分
-1.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.17 |
|
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 29.68% |
| 机构持股比例 | 29.11% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合